Literature DB >> 18678629

Last Word on Point:Counterpoint: The major limitation to exercise performance in COPD is 1) inadequate energy supply to the respiratory and locomotor muscles, 2) lower limb muscle dysfunction, 3) dynamic hyperinflation.

Andrea Aliverti1, Peter T Macklem.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18678629     DOI: 10.1152/japplphysiol.90745.2008

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


× No keyword cloud information.
  5 in total

1.  Impaired central hemodynamics in chronic obstructive pulmonary disease during submaximal exercise.

Authors:  Joshua R Smith; Bruce D Johnson; Thomas P Olson
Journal:  J Appl Physiol (1985)       Date:  2019-07-11

2.  Effects of eccentric, concentric and eccentric/concentric training on muscle function and mass, functional performance, cardiometabolic health, quality of life and molecular adaptations of skeletal muscle in COPD patients: a multicentre randomised trial.

Authors:  Luis Peñailillo; Denisse Valladares-Ide; Sebastián Jannas-Velas; Marcelo Flores-Opazo; Mauricio Jalón; Laura Mendoza; Ingrid Nuñez; Orlando Diaz-Patiño
Journal:  BMC Pulm Med       Date:  2022-07-19       Impact factor: 3.320

3.  Oxygen desaturation during the six-minute walk test in COPD patients.

Authors:  Maria Ângela Fontoura Moreira; Gabriel Arriola de Medeiros; Francesco Pinto Boeno; Paulo Roberto Stefani Sanches; Danton Pereira da Silva Júnior; André Frotta Müller
Journal:  J Bras Pneumol       Date:  2014 May-Jun       Impact factor: 2.624

4.  More Impaired Dynamic Ventilatory Muscle Oxygenation in Congestive Heart Failure than in Chronic Obstructive Pulmonary Disease.

Authors:  Ming-Lung Chuang; I-Feng Lin; Meng-Jer Hsieh
Journal:  J Clin Med       Date:  2019-10-07       Impact factor: 4.241

5.  Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial.

Authors:  Lucas Boeck; Michael Tamm; Peter Grendelmeier; Daiana Stolz
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.